Kemin’s FloraGLO Legacy Continues with New Blue Light Protection Patent

636040850652417747eyehealth.jpg

14 Jul 2016 --- The United States Patent and Trademark Office has issued Kemin Industries a patent for the role of its products in protecting individuals with three common ocular disorders from blue light or light-induced damage.

The royalty-free license for these products (FloraGLO Lutein and ZeaONE Zeaxanthin, distributed by DSM as OPTISHARP Natural) will provide a ‘huge market opportunity.’
 
Kemin’s patent (US Patent No. 9,226,940 B2) allows vitamin and dietary supplement manufacturers using FloraGLO and/or ZeaONE to position their products for blue light protection. The patent specifically covers products containing ocular antioxidants including lutein and zeaxanthin employed to protect the eye from light-induced damage, particularly the damage caused by the blue wavelengths of light.
 
The patent targets individuals with presbyopia, hyperopia or astigmatism. In these three conditions, blue wavelengths of light are focused directly onto the macula, creating a higher risk for ocular damage.
 
Blue light impacts the majority of adults ages 45 and older who have presbyopia, commonly known as age-related farsightedness.
 
“Because of the widespread prevalence of presbyopia, this patent opens the door for FloraGLO and OPTISHARP Natural customers to make blue light eye protection claims when targeting consumers 45 years and older,” said Dr. Richard Roberts, Patent Inventor and Principal Manager of Scientific Affairs and Technical Services for the Human Nutrition and Health division of Kemin.
 
Nearly every source of light—whether natural or artificial—emits harmful blue wavelengths of light.
The growing prevalence of digital devices like computers, tablets and smartphones is exposing individuals to more blue light than ever before.
 
Over half of Americans use digital devices more than five hours a day and 70% use two or more devices at the same time.
 
In addition to blue light from digital devices, the use of the light emitting diode (LED) in indoor lighting is another growing source of blue light exposure. LED bulbs contain 35% blue light levels as compared to 3% levels in traditional incandescent bulbs. In North America alone, LED lighting made up a US$4.8 billion market in 2012 and is expected to make up a US$42 billion market by 2019.
 
As blue light levels and sources continue to grow, children are especially vulnerable to the effects. Blue light exposure is especially concerning for infants and young children, as nearly every child is born with hyperopia, commonly known as farsightedness. Because of the condition, they are at a higher risk for blue light and light-induced damage as their eyes develop.
 
“Children are exposed to blue light more than ever before. Believe it or not, greater than half of American children use digital devices two or more hours a day,” said Heather Richardson, Vision Platform Senior Product Manager for the Human Nutrition and Health division of Kemin. “Our patent can help customers address this growing concern and develop blue light protection products for kids.”
 
“We are pleased to be able to offer a royalty-free license of our patent to customers who are interested in marketing blue light protection products to adults 45+ and children ages 0-2,” said Anita Norian, President of the Human Nutrition and Health division of Kemin. “It is clear this will be a huge market opportunity for our customers as the concern of blue light exposure and consumer awareness grows.”

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Health & Nutrition News

Living by a forest diversifies kid’s micronutrient intake, study finds

17 Aug 2018 --- A global study has found that children who live near forests enjoy a better nutrition intake than those who live further away from them. The research, which was conducted across 27 developing countries, identified that children living by forests had at least 25 percent greater diversity in their diets compared to kids who did not. The study, published in Science Advances, notes particular nutrient increases with vitamin A and iron. The findings have the potential for actors attempting to lessen malnutrition through interventions such as fortification, by highlighting the benefit that could come from an integrated approach.

Health & Nutrition News

Low-carb diets could shorten life by four years, warns Lancet study

17 Aug 2018 --- Following a low-carb diet could shorten life expectancy by four years, suggests new research published in The Lancet Public Health. The high levels of animal fats and proteins that often replace carbohydrates in typical low-carb diets appear to be associated with the higher risk of mortality. Eating more plant-based proteins and fats in place of carbohydrates was linked to lower mortality and even reversed the greater mortality risk. 

Health & Nutrition News

Weekly Roundup: US consumers rank clean water as top health desire, high protein diet reduces risk of diabetes for those with fatty liver

17 Aug 2018 --- The weekly roundup is NutritionInsight's collection of global nutrition stories from the past week. A Nestlé Waters commissioned survey found that clean water is the most important health factor to US consumers and a study found that increasing the amount of protein in the diet may reduce the risk of diabetes in people with Non-Alcoholic Fatty Liver Disease (NAFLD). Australia based Freedom Foods acquired protein product brand Crankt to strengthen its position in the sports nutrition market. The European Commission (EC) approved an application from DSM Europe to rename the carotenoid zeaxanthin in the novel food register. CBI and Campden BRI are teaming up for a Colombian product development workshop and, lastly, the Council for Responsible Nutrition (CRN) announced eleven new additions to its membership ranks.

Health & Nutrition News

Omega 3 platforms: BASF targets Non-Alcoholic Fatty Liver Disease as scientific support behind intervention grows

16 Aug 2018 --- BASF is targeting Non-Alcoholic Fatty Liver Disease (NAFLD) with Hepaxa, its first-to-market omega 3 product dedicated to the dietary management of the disease. Hepaxa increases the levels of fatty omega 3 acids in patients, which improves the liver's ability to process fat. Importantly, Hepaxa is manufactured using a patented purification technology which removes certain pollutants known to harm NAFLD patients. A recent meta-analysis of 18 studies, in part funded by BASF, has highlighted the importance of omega 3 intakes among people who have NAFLD.

Health & Nutrition News

Morning workout: Speed up your metabolism with breakfast, study suggests

15 Aug 2018 --- Eating breakfast before exercise may “prime” the body to burn carbohydrates during exercise and more rapidly digest, absorb and metabolize food after working out, University of Bath researchers have shown in a study published in American Journal of Physiology: Endocrinology and Metabolism.

More Articles
URL : http://www.nutritioninsight.com:80/news/kemins-floraglo-legacy-continues-with-new-blue-light-protection-patent.html